Ovarian and Fallopian Tube Cancer
pharmaand GmbH supports clinical research in ovarian epithelial cancer, including advanced disease and high-grade epithelial ovarian cancer. Its activity also extends to fallopian tube cancer and related primary peritoneal cancer populations.
- Maintenance treatment in ovarian cancer
- Platinum-sensitive disease
- Advanced gynecologic malignancies
The sponsor’s research interest is centered on post-treatment disease control in women with platinum-responsive gynecologic cancers.
Peritoneal Malignancies
Research activity includes malignant peritoneal neoplasm and primary peritoneal cancer, with attention to tumors that share biological and clinical features with ovarian cancer.
- Peritoneal cancer
- Gynecologic oncology
- Advanced-stage abdominal malignancy
These areas reflect interest in cancers arising within the peritoneal cavity and in treatment strategies used after initial systemic therapy.
Targeted Oncology
The sponsor’s trial portfolio includes study of rucaparib, a PARP inhibitor, in settings relevant to homologous recombination deficiency and tumor maintenance therapy.
- PARP inhibition
- Homologous recombination deficiency
- Oral anticancer therapy
This indicates a therapeutic focus on DNA repair–targeted oncology for tumors with limited options after front-line chemotherapy.
Immuno-Oncology Combinations
pharmaand GmbH is also involved in research combining nivolumab with targeted therapy in gynecologic cancer, reflecting interest in immune checkpoint blockade alongside maintenance regimens.
- Immune checkpoint therapy
- Combination maintenance strategies
- Ovarian cancer immunotherapy
Its clinical activity spans treatment approaches aimed at extending disease control in recurrent-risk ovarian and peritoneal cancers.
